The US pharmacy chain, Walgreens, plans to start selling a new genetic test at many of its 7,500 US outlets this month. The genetic test, created by Pathway Genomics and called Insight Saliva Collection Kit is said to be able to predict an individual’s risk of developing disease, as well as his/her potential response to specific medications.

In pre-pregnancy planning, females and their partners might be able to predict the risk of several genetic diseases that are caused by recessive genes – diseases which offspring could inherit from their parents, Pathway Genomics says.

The Insight Saliva Collection Kit will retail in the $20 to $30 price range. It contains a small saliva collection kit, straightforward instructions, and a postage-paid envelope which the user sends to the Pathway Genomics laboratory. Test results can be viewed in the Pathway’s web site on a secure, password-protected account.

The customer will be able to see his/her:

  • Individualized Genetic Insight Report for Drug Response ($79)
  • Pre-Pregnancy Planning ($179)
  • Health Conditions ($179)
  • A combination of all three ($249)

Jim Plante, CEO of Pathway Genomics, said “We’re revolutionizing the way people access information about their genetics, and through thousands of convenient Walgreens locations, we’re making it easier and more affordable than ever before to order a personalized genetic report. The value of knowing how genes play a role in our personal lives, and potentially the lives of our children, is critical for making well-informed health and wellness decisions.”

According to a Pathway Genomics press release “..personalized genetic reports are quickly becoming a critical component for providing useful insight into a person’s DNA make up and genetic data. For instance, a Pathway Genomics Genetic Insight Report can provide a wide range of information to help an individual learn about their health and make healthier lifestyle choices.”

With a Pathway Genomics Genetic Insight Report for prescription medications, people can discover if due to their genetic traits, they are more or less sensitive to a variety of treatment therapies.

Source: Pathway Genomics

Written by Christian Nordqvist